Expansion of Research Programme with Imperial College London

10 September 2019, London. EMMAC, the leading European independent medical cannabis company, is pleased to announce an expansion of its research collaboration with Imperial College London. The new research programme aims to evaluate the “entourage effect” of cannabinoids for pain using in vitro models, and the mechanisms of action in a range of medicinal cannabis combination products. The publication of such evidence would enable its citation in EMMAC information documents as well as support future clinical trials in patients with acute or chronic pain.

This expanded collaboration between EMMAC and Imperial College London adds to the long-term comprehensive research programme underway, designed to inform and shape the future of medical cannabis therapies. The overall programme aims to investigate mechanisms of action of cannabis-based medicinal products related to several clinical applications, including pain and cancer, as well as characterise cannabis-based medicinal products in disease-specific models with a focus on translation to clinical trials.

Under the terms of the new Collaboration Agreement signed between the parties, EMMAC will fund a post-doctoral research fellow for an extendable one-year period, to explore the efficacy of EMMAC products in neuropathic pain to support their development towards clinical trials.

Strategic Highlights

• Additional research through the Collaboration Agreement with Imperial College London;

• EMMAC to fund research staff for an extendable one-year period, to explore the basic cannabinoid mechanisms in neuropathic pain and translate these to clinical trials;

• Research provides valuable data and intellectual property in relation to the use of cannabinoids to treat acute and chronic pain, nausea and vomiting;

• EMMAC expected to partner with Imperial on additional cannabinoid research programmes focused across different therapeutic areas;

• Partnership with world-renowned institution confirms EMMAC as a European leader in research supporting the growing medical cannabis industry.

Professor Praveen Anand, Imperial College London, said: “This is a very exciting area of pain research, which aims to characterise the entourage effect and related mechanisms of cannabis-based medicine combinations at a molecular level. Our results may support the rational design of future clinical trials to enhance pain relief and minimise adverse effects. We look forward to working with EMMAC in developing these experimental platforms and pipelines, to advance the treatment of patients with neuropathic pain.”

Tom Rooke, Chief Operating Officer of EMMAC, commented: “The strategic partnership between EMMAC and Imperial College London is important to advancing the industry’s understanding of the medical benefits of cannabis, and as a result of the mutually positive and productive experience of working together, we are delighted Imperial College has chosen us as academic partner in the UK to expand our existing research programme.”


EMMAC Life Sciences Ltd is the leading European independent medical cannabis company, working to join together the latest science and research with cutting-edge cultivation, extraction and production. With supply and distribution partnerships throughout Europe, EMMAC is working to establish itself as both a thought leader in the industry, as well as the European leader in the production and supply of medical cannabis, hemp and other derivative products.

About Imperial College London

Imperial College London is one of the world’s leading universities. The College’s 17,000 students and 8,000 staff are expanding the frontiers of knowledge in science, medicine, engineering and business, and translating their discoveries into benefits for our society.

Founded in 1907, Imperial builds on a distinguished past – having pioneered penicillin, holography and fibre optics – to shape the future. Imperial researchers work across disciplines to improve health and wellbeing, understand the natural world, engineer novel solutions and lead the data revolution. This blend of academic excellence and its real-world application feeds into Imperial’s exceptional learning environment, where students participate in research to push the limits of their degrees.

Imperial is the UK’s most international university, according to Times Higher Education, with academic ties to more than 150 countries. Reuters named the College as the UK’s most innovative university because of its exceptional entrepreneurial culture and ties to industry.



For scientific enquiries please contact research@emmac.com

For general enquiries please contact info@emmac.com or visit www.emmac.com

Media enquiries:
Henry Harrison-Topham / Jamie Hooper / Ariadna Peretz Tel: +44 (0) 20 7466 5000
emmac@buchanan.uk.com  www.buchanan.uk.com


All statements, other than statements of historical fact, in this news release are forward-looking statements that involve various risks and uncertainties, including, without limitation, statements regarding potential values, the future plans and objectives of EMMAC Life Sciences Limited. There can be no assurance that such statements will prove to be accurate, achievable or recognisable in the near term.
Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. EMMAC Life Sciences Limited assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.